Naris Nilubol, M.D., F.A.C.S.
- Center for Cancer Research
- National Cancer Institute
- Building 10 - Room 45952
- Bethesda, MD 20892
- 240-760-6154
- niluboln@mail.nih.gov
RESEARCH SUMMARY
Dr. Nilubol is a surgeon-scientist specialized in endocrine oncology surgery and clinical research involving thyroid, parathyroid, adrenal, and neuroendocrine tumors. His laboratory research focus includes the identification of novel targeted therapeutics in endocrine cancers and novel cancer drug delivery methods by targeting tumor microenvironment.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Naris Nilubol, M.D., F.A.C.S.
Clinical Trials
Research
Dr. Nilubol is the Principle Investigator of the protocol that comprehensively analyzes molecular alterations in endocrine cancers that lead to tumor progression and metastasis. He is the Principle Investigator who aims to risk-stratify patients with von Hippel-Lindau disease (VHL)-associated pancreatic neuroendocrine tumors by combining the advanced imaging modalities, genetic information, and the molecular mechanisms involved in early metastasis identified by mRNA profiling, metabolomics, and exosomes.
Dr. Nilubol’s research program focuses on the identification of novel targeted therapeutics in endocrine cancers such as adrenocortical cancer and aggressive variants of thyroid cancers. Patients with these rare and aggressive cancers do not have treatment options with a durable response. Dr. Nilubol collaborates with a number of NIH intramural investigators and uses the quantitative high-throughput drug screening method to identify candidate compounds from several pharmaceutical libraries containing approved drugs and natural compounds. Candidate compounds are being investigated in preclinical studies with the goal to translate the effective combinations of drugs to clinical trials in patients with advanced endocrine cancers. However, most newly-discovered drugs do not show anti-tumor efficacy because many characteristics of solid cancers prohibit effective drug delivery. Thus, Dr. Nilubol’s research focuses on targeting the tumor microenvironment to reduce interstitial fluid pressure and increase drug delivery. To accomplish this goal, he utilizes gold nanomedicine carrying vascular disrupting agent (tumor necrosis factor-alpha) specifically targeting tumor cells and their blood supply in collaborating with extramural investigators. The current research aim is to understand how TNF-α works in the tumor microenvironment and how to induce the response downstream to TNF-α in tumors refractory to TNF-α.
Publications
- Bibliography Link
- View Dr. Nilubol's PubMed Summary.
Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors
Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure
High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy
Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness
Biography
Naris Nilubol, M.D., F.A.C.S.
Dr. Nilubol graduated from Chulalongkorn University Medical Center, Bangkok, Thailand with honors. He completed a surgical research fellowship followed by general surgery training in 2005 at The Mount Sinai Hospital, New York, NY. Following surgery residency, Dr. Nilubol completed the Endocrine Oncology Surgery fellowship at Rush University Medical Center, Chicago, IL. Dr. Nilubol was on faculty at Mount Sinai Hospital, NY, before being recruited to NCI. There are over 140 peer-reviewed publications and several book chapters that Dr. Nilubol has authored.